Skip to Content

Project 4: Targeting the PI3K Pathway in Ovarian Cancer

Publications

Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Shayesteh L., Lu Y, Kuo WL, Baldocchi R., Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 1999; 21:99-102. PMID: 9916799.
    Abstract
  2. Zebrowski BK, Liu W, Ramirez K, Akagi, MD, Mills GB, Ellis, LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites: Ann Surg Oncol 1999; 6:373-8. PMID: 10379858.
    Abstract
  3. Mills GB, Schmandt R, Gershenson D, Bast RC Jr. Editorial: Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clinical Cancer Research 1999; 5:2286-8. PMID: 10499594.
    Full Text
  4. Mills GB, Lu Y, Shyestri L, Pinkel D, Gray J. From genetics to therapeutic targets: Phosphatidylinositol 3’ kinase (PI3K) in ovarian and breast cancer. In: Cancer: investigacion basica y aplicaciones clinicas: M. Barbacid (ed.) Erika Med 1999; 6-16. [no PMID]
    [no link available]
  5. Fang X, Lu, Y, Yu SX, Bast RC Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000; 97:11960-5. PMCID: PMC17277.
    Abstract
  6. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor. Clin Cancer Res 2000;6:880-6. PMID: 10741711.
    Abstract
  7. Suzuki S, Moore II D, Ginzinger D, Godfrey T, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu KH, Mills GB, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 2000;60:5382-5. PMID: 11034075.
    Abstract
  8. Asselin E, Mills GB, Tsang BK. XIAP regulates AKT activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian surface epithelial cancer cells. Cancer Research 2001; 61:1862-8. PMID: 11280739.
    Abstract
  9. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001; 28:125-41. PMID: 11706404.
    Abstract
  10. Lu Y, Shayestri L, Lapushin R, Yu S, Cuevas B, Fang X, Eder A, Furui T, Plikoff D, Kuo WL, Baldocchi R, Vanhaesebroeck B, Pinkel D, Siminovitch K, Jaffe R, Gray J, Mills GB. Phosphatidylinositol 3’kinase as a target in selected ovarian cancers: from genomics to therapeutics. In: Textbook of Ovarian Cancer Jacobs I, Hudson C, Shepherd J. Oram D., Blackett A., Luelsey D, Berchuck A (eds.). Oxford University Press, 2001;413-422. [no PMID]
    [no link available]
  11. Mills GB, Lu Y, Kohn E. Commentary: Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the phosphatidylinositol 3-kinase pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98:10031-3. PMCID: PMC56908.
    Full Text
  12. Mujoo K, Haridas V, Hoffman JJ, Wachter GA, Hutter LK, Lu Y, Blake MA, Jayatilake, GS, Bailey D, Mills GB, Gutterman JU. Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res 2001; 61:5486-90. PMID: 11454696.
    Abstract
  13. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth J, Mills GB, Wolf J. Identification of tissue- and cancer-selective promoters for introduction of genes into human ovarian cancer cells. Gynecol Oncol 2002; 85:451-8. PMID: 12051873.
    Abstract
  14. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62:1087-92. PMID: 11861387.
    Abstract
  15. Tanyi JL, Cheng KW, Lahad JP, Mills GB. Genomic technologies in cancer research, drug discovery and development. CME Journal of Gynecologic Oncology 2002; 7:16–24. [no PMID]
    [no link available]
  16. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002; 161:1917-24. PMCID: PMC1850791.
    Abstract
  17. Kohn EC, Fidler IJ, Fishman D, Jaffe R, Liotta LA, Van Trappen P, Mills GB, and Trope C. Discussion: Metastasis and angiogenesis in epithelial ovarian cancer therapeutics in ovarian cancer. Gynecol Oncol 2003; 88(Suppl):S37-42. [no PMID]
    Abstract
  18. Liotta LA, Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC. Proteomic patterns in sera serve as biomarkers of ovarian cancer: Gynecol Oncol 2003; 88 (Suppl):S25-8. PMID: 12586081.
    Abstract
  19. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 2003; 278:40057-66. PMID: 12869565.
    Abstract
  20. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-22. PMID: 12743604.
    Abstract
  21. Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of gynecological cancer. Int J Gynaecol Obstet 2003; 83 (Suppl1):203-9. PMID: 14763176.
    Abstract
  22. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 2003; 30:93-104. PMID: 14613030.
    Abstract
  23. Cheng KW, Lahad JP, Mills GB. Analysis of molecular aberration in ovarian cancer allows novel target identification. J Obstet Gynaecol Can 2004; 25(5): 461-74. PMID: 15151733.
    [no link available]
  24. Lu Y, Wang H, Mills GB. Targeting the PI3K/AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003; 7:205-28. PMID: 14763163.
    Abstract
  25. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer, 2003; 3(8):582-91. PMID: 12894246.
    Abstract
  26. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi G, Mills GB. Molecular therapeutics: promise and challenges. Semin Oncol 2004; 31:39-53. PMID: 15052542.
    Abstract
  27. Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Seminars in Oncology, 2004 Dec;31(6 Suppl 16):10-7. PMID: 15799239.
    Abstract
  28. Drees BE, Mills GB, Rommel C, Prestwich GD. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opinion on Therapeutic Patents 2004; 14(5): 703-732. [no PMID]
    Full Text
  29. Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, Ferrara N, Jaffe RB, Brasch RC. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000; 183(4): 956-63. PMID: 11035346.
    Abstract
  30. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003; 9: 5721-8. PMID: 14654557.
    Abstract
  31. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest. 2004;22 Suppl 2:29-44. Review. PMID: 15573743.
    Abstract
  32. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML, Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res. 2005 Jul 1;11(13):4968-76. PMID: 16000597.
    Abstract
  33. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005 Apr;4(4):346-55. Epub 2005 Jan 25. Review. PMID: 15671044.
    Abstract
  34. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12519-24. Epub 2005 Aug 22. PMCID: PMC1188258.
    Abstract
  35. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K-Akt pathway for cancer drug discovery. Nature Reviews Drug Discovery 2005; 4:988-1004. PMID: 16341064.
    Abstract
  36. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, and Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8. PMID: 16452206.
    Abstract
  37. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. Journal Clinical Oncology: I24:354-360, 2006. PMID: 16421416.
    Abstract
  38. Rai R, Dai H, Multani AS, Li K, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell: 10:145-57, 2006. PMCID: PMC1557410.
    Abstract
  39. Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualized cancer therapy. Expert Opinion in pharmacotherapy 7:2243-61, 2006. PMID: 17059381.
    Abstract
  40. Fang D, Hawke D, Zheng Y, Xian Y, Miesenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z, Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity J Biol Chem 282:11221-9, 2007. PMCID: PMC1850976.
    Abstract
  41. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res. 2007 Apr 1;67(7):3074-84. PMID: 17409414.
    Abstract
  42. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell. 2007 Aug;12(2):104-7. Review. PMID: 17692802.
    Abstract
  43. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007 Dec 15;13(24):7421-31. PMID: 18094426.
    Abstract
  44. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, Mills GB, Auersperg N. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci. 2008 Mar 1;121(Pt 5):664-74. Epub 2008 Feb 12. PMID: 18270270.
    Abstract
  45. Garlich JR, De P, Dey N, Su JD, Miller T, Shu HK, Mills GB, Lu Y, Vogelstein B, Diaz L, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68:206-15, 2008. PMID: 18172313.
    Abstract
  46. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin-resistance in Brca1/p53-mediated mammary tumor. Cancer Research 68:3243-50, 2008. PMID: 18451150.
    Abstract
  47. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes K, Mills GB. Individualized molecular medicine: Linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol. 622:183-95, 2008. PMID: 18546628.
    Abstract
  48. Agarwal R, Carey M, Hennessy B, Mills GB. PI3-kinase pathway directed therapeutic strategies in cancer. Current Opinion in Investigational Drugs, 2008. [no PMID]
    [no link available]
  49. Hennessy B, Bast RC, Gonzalez-Angulo AM, Mills GB. Early Detection of Cancer: Molecular Screening. In: Molecular Basis of Cancer. Mendelsohn, Israel, Gray, Thompson, Editors. Saunders Elsevier, Philadelphia, pages 335-347, 2008. [no PMID]
    [no link available]
  50. Bast RC, Mills GB. Molecular pathogenesis of epithelial ovarian cancer. In: Molecular Basis of Cancer. Mendelsohn, Israel, Gray, Thompson, Editors. Saunders Elsevier, Philadelphia, pages 441-454, 2008. [no PMID]
    [no link available]
  51. Hennessy BT, Carey M, Naora H, Agarwal R, Mills GB. Ovarian Cancer: Molecular, Cellular and Clinical Biology. M Markman, R Bast, Editors, 2008. [no PMID]
    [no link available]
  52. Yim EY, Peng G, Dai H, Hu R, Li K, Lu Y, Mills G, Meric-Bernstam F, Hennessy B, Craven R, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15:304-315, 2009. PMCID: PMC2673492.
    Abstract
  53. Ihle N, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenicRas is a dominant predictor for resistance. Cancer Research 69:143-50, 2009. PMCID: PMC2613546.
    Abstract
  54. Siwak DR, Carey M, Hennessy BT, Nguyen CT, Nolden L, Mills GB. The Epidermal Growth Factor Receptor in Ovarian Cancer: Current Knowledge, Future Challenges, Current Biodata. In Press. [no PMID]
  55. Mills GB, Agarwal R, Cheng KW. Ras-superfamily GTP-ase in ovarian cancer. In: Ovarian Cancer. S Stack, D Fishman, Editors, In Press. [no PMID]

© 2014 The University of Texas MD Anderson Cancer Center